Business, energy, technology, markets and global industry news from Business News Today

CD3

PharmaDeviceNews CD3
Representative image: Antengene’s ATG-106 licensing deal highlights growing biotech interest in CDH6 x CD3 T cell engagers for solid tumor immunotherapy.
Pharma & Biotech

Antengene, K2 Therapeutics deal signals fresh momentum for solid tumor TCEs

Find out how Antengene’s ATG-106 licensing deal could shape the next phase of solid tumor T cell engager development.

Read More
Representative image: Biomedical researchers analyse immune-cell data in a laboratory setting, reflecting the scientific focus behind Antengene’s ATG-207 preclinical autoimmune therapy program and its CD3 and TGF-beta fusion approach.
Pharma & Biotech

Antengene brings first ATG-207 preclinical data to EULAR 2026 as autoimmune focus deepens

Find out how Antengene’s ATG-207 data could shape autoimmune drug development as CD3 and TGF-beta fusion biology enters focus.

Read More
Representative image of advanced autoimmune drug research, reflecting UCB’s proposed acquisition of Candid Therapeutics and the rising focus on T-cell engager therapies.
Pharma & Biotech

Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?

UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.

Read More
Pharma & Biotech

Why Innovent Biologics’ tri-specific IBI3055 matters in the race to deplete both B cells and plasma cells

Innovent Biologics unveiled preclinical IBI3055 data in autoimmune disease. Read what this could change for immune-reset therapies.

Read More
Pharma & Biotech

How Celltrion’s HER2–CD3 bispecific could compete in the T-cell engager arena

Celltrion is going all-in on oncology biologics with ADCs, msAbs, and U.S. biomanufacturing scale-up. Find out what this shift means for global competition.

Read More